中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(8): 1533-1540

Clinical features of chronic hepatitis C patients with genotype 3 infection： A multicenter retrospective cohort study

DOI: 10.12449/JCH250811
  • 1.

    Department of Infectious Diseases，The Second Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710004，China

  • 2.

    Department of Infectious Diseases，Xi’an Central Hospital，Xi’an 710003，China

  • 3.

    Department of Infectious Diseases，Wuwei People’s Hospital，Wuwei，Gansu 733000，China

  • 4.

    Department of Infectious Diseases，Xijing Hospital，Air Force Medical University，Xi’an 710032，China

  • 5.

    Department of Hepatology，Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University，Urumqi 830000，China

  • 6.

    Department of Infectious Diseases，Tangdu Hospital，Air Force Medical University，Xi’an 710032，China

  • 7.

    Department of Hepatology，The Fourth People’s Hospital of Qinghai Province，Xining 810007，China

  • 8.

    Department of Infectious Diseases，The First Hospital of Lanzhou University，Lanzhou 730000，China

  • 9.

    Department of Infectious Diseases，People’s Hospital of Xinjiang Autonomous Region，Urumqi 830001，China

  • 10.

    Shaanxi Provincial Clinical Medical Research Center of Infectious Diseases，Xi’an 710061，China

Research funding:

National Natural Science Foundation of China (82170626);

National Natural Science Foundation of China (82473291);

Innovation and entrepreneurship training program of Xi’an Jiaotong University (SJ202210698323);

Science and technology plan project of Xi’an City (22YXYJ0043)

More Information
  • Corresponding author: FU Jianjun， fjianj@163.com （ORCID： 1234-2345-3456-4567）; GAO Ning， gaohuining1@163.com （ORCID： 1234-2345-3456-4567）
  • Received Date: 2025-01-02
  • Accepted Date: 2025-02-11
  • Published Date: 2025-08-25
    Abstract
  •   Objective  To investigate the clinical features of chronic hepatitis C （CHC） patients with hepatitis C virus genotype 3 （HCV GT3） infection and the risk factors for disease progression.  Methods  A multicenter retrospective cohort study was conducted among 1 002 CHC patients from 11 clinical centers in Northwest China from December 2017 to November 2023， and according to their genotype， they were divided into GT1， GT2， GT3， and GT6 groups. Clinical features were compared between the patients with different genotypes. The one-way analysis of variance was used for comparison of normally distributed continuous data between groups， and the Scheffe test was used for further comparison between two groups. The Kruskal-Wallis H test was used for comparison of data with skewed distribution between groups； the chi-square test or Fisher test was used for comparison of categorical data between groups. The multivariate logistic regression analysis was used to explore the influencing factors for the progression of CHC to liver cirrhosis.  Results  In terms of the genotype， there were 427 patients with GT1 infection， 242 with GT2 infection， 299 with GT3 infection （210 patients with GT3a infection， 87 with GT3b infection， and 2 with unclassified genotype）， and 34 with GT6 infection. The patients with GT3 infection had a significantly younger age than those with GT1 infection （51.3±0.5 years vs 53.2±0.6 years， P<0.05） or GT2 infection （51.3±0.5 years vs 53.7±0.8 years， P<0.05）， and for the patients with liver cirrhosis， the patients with GT3 infection had a significantly younger age than those with GT1 infection （52.1±0.5 years vs 59.4±0.9 years， P<0.001） or GT2 infection （52.1±0.5 years vs 58.1±1.1 years， P<0.001）. Among the patients with GT3 infection， male patients accounted for 77.9% and the patients with liver cirrhosis accounted for 46.2%， which were significantly higher than those among the patients with GT1， GT2 or GT6 infection （all P<0.001）. At baseline， the patients with GT3 infection had significantly higher levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） than those with GT1 or GT2 infection， significantly higher aspartate aminotransferase-to-platelet ratio index （APRI） and fibrosis-4 （FIB4） than those with GT1， GT2 or GT6 infection， a significantly lower platelet count （PLT） than those with GT2 or GT6 infection， a significantly higher level of alpha-fetoprotein than those with GT2 or GT6 infection， and a significantly lower level of albumin （Alb） than those with GT6 infection （all P<0.05）. There were no significant differences between the patients with GT3a infection and those with GT3b infection in age， sex， the proportion of patients with liver cirrhosis， comorbidities， HCV RNA quantification， PLT， ALT， AST， alkaline phosphatase， Alb， APRI， and FIB-4 （all P>0.05）. The multivariate logistic regression analysis showed that PLT≤150×109/L （odds ratio ［OR］=10.72， 95% confidence interval ［CI］： 5.76‍ ‍—‍ ‍35.86， P<0.001） and Alb≤35 g/L （OR=3.74， 95%CI： 1.22‍ ‍—‍ ‍11.45， P=0.021） were risk factors for liver cirrhosis.  Conclusion  Most CHC patients with GT3 infection are male in Northwest China， and compared with the patients with other genotypes， such patients tend to have a younger age of onset and higher degrees of liver inflammation activity and fibrosis. Low PLT and a low level of Alb are risk factors for progression to liver cirrhosis in CHC patients with GT3 infection.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infections Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.
    [3]
    Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2( 3): 161- 176. DOI: 10.1016/S2468-1253(16)30181-9.
    [4]
    MESSINA JP, HUMPHREYS I, FLAXMAN A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J]. Hepatology, 2015, 61( 1): 77- 87. DOI: 10.1002/hep.27259.
    [5]
    RAO HY, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29( 3): 545- 553. DOI: 10.1111/jgh.12398.
    [6]
    TANG Q, CHEN ZW, LI H, et al. Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis[J]. Infect Dis Poverty, 2023, 12( 1): 66. DOI: 10.1186/s40249-023-01106-y.
    [7]
    CHEN Y, YU CS, YIN XR, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China[J]. Emerg Microbes Infect, 2017, 6( 11): e95. DOI: 10.1038/emi.2017.77.
    [8]
    LI F, LI B, ZHU QY. Research progress on the epidemiological characteristics and diagnosis of hepatitis C in China[J]. Int J Virol, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.

    黎锋, 李博, 朱秋映. 中国丙肝流行特征与诊断研究进展[J]. 国际病毒学杂志, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.
    [9]
    BOJANIC K, BOGOJEVIC MS, VUKADIN S, et al. Noninvasive fibrosis assessment in chronic hepatitis C infection: An update[J]. J Clin Transl Hepatol, 2023, 11( 5): 1228- 1238. DOI: 10.14218/JCTH.2022.00365.
    [10]
    JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.
    [11]
    HUANG CF, IIO E, JUN DW, et al. Direct-acting antivirals in East Asian hepatitis C patients: Real-world experience from the REAL-C Consortium[J]. Hepatol Int, 2019, 13( 5): 587- 598. DOI: 10.1007/s12072-019-09974-z.
    [12]
    HUANG R, RAO HY, XIE Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection[J]. J Med Virol, 2019, 91( 7): 1313- 1318. DOI: 10.1002/jmv.25454.
    [13]
    WU N, RAO HY, YANG WB, et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort[J]. Chin Med J(Engl), 2020, 133( 3): 253- 261. DOI: 10.1097/CM9.0000000000000629.
    [14]
    DEGENHARDT L, PEACOCK A, COLLEDGE S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review[J]. Lancet Glob Health, 2017, 5( 12): e1192- e1207. DOI: 10.1016/S2214-109X(17)30375-3.
    [15]
    ADINOLFI LE, UTILI R, ANDREANA A, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C[J]. Dig Dis Sci, 2001, 46( 8): 1677- 1683. DOI: 10.1023/a:1010697319589.
    [16]
    LIU CR, LI X, CHAN PL, et al. Prevalence of hepatitis C virus infection among key populations in China: A systematic review[J]. Int J Infect Dis, 2019, 80: 16- 27. DOI: 10.1016/j.ijid.2018.11.006.
    [17]
    HAQUE LY, FIELLIN DA, TATE JP, et al. Association between alcohol use disorder and receipt of direct-acting antiviral hepatitis C virus treatment[J]. JAMA Netw Open, 2022, 5( 12): e2246604. DOI: 10.1001/jamanetworkopen.2022.46604.
    [18]
    IM PK, MILLWOOD IY, KARTSONAKI C, et al. Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: A 10-year prospective study of 0.5 million adults[J]. BMC Med, 2021, 19( 1): 216. DOI: 10.1186/s12916-021-02079-1.
    [19]
    PREMKUMAR M, ANAND AC. Tobacco, cigarettes, and the liver: The smoking Gun[J]. J Clin Exp Hepatol, 2021, 11( 6): 700- 712. DOI: 10.1016/j.jceh.2021.07.016.
    [20]
    WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4( 2): 127- 134. DOI: 10.1016/S2468-1253(18)30343-1.
    [21]
    JI FP, TRAN S, OGAWA E, et al. Real-world effectiveness and tolerability of interferon-free direct-acting antiviral for 15, 849 patients with chronic hepatitis C: A multinational cohort study[J]. J Clin Transl Hepatol, 2024, 12( 7): 646- 658. DOI: 10.14218/JCTH.2024.00089.
    [22]
    ABULITIFU YLHM, LIAN JS, BALI RML, et al. Efficacy and safety of Sofosbuvir/Velpatasvir or combined with Ribavirin in treatment of patients with hepatitis C related cirrhosis in Xinjiang region[J]. Chin J Clin Infect Dis, 2022, 15( 6): 459- 463. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.005.

    依力哈木·阿不力提甫, 连江山, 热米拉·巴力, 等. 索磷布韦/维帕他韦单用或联合利巴韦林治疗新疆地区丙型肝炎肝硬化患者的疗效及安全性分析[J]. 中华临床感染病杂志, 2022, 15( 6): 459- 463. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.005.
    [23]
    LIU YY, LIU N, FU JJ, et al. Distribution characteristics of hepatitis C virus genotypes in Shaanxi Province[J]. Hainan Med J, 2021, 32( 4): 413- 416. DOI: 10.3969/j.issn.1003-6350.2021.04.002.

    刘媛媛, 刘娜, 付建军, 等. 陕西省丙型肝炎病毒基因型分布特征[J]. 海南医学, 2021, 32( 4): 413- 416. DOI: 10.3969/j.issn.1003-6350.2021.04.002.
    [24]
    ZHANG HY, RAO HY, CHEN HS. Current status of hepatitis C virus infection and progress in its elimination in China[J]. J Clin Hepatol, 2024, 40( 4): 649- 653. DOI: 10.12449/JCH240401.

    张海莹, 饶慧瑛, 陈红松. 中国丙型肝炎病毒感染的现状及清除进程[J]. 临床肝胆病杂志, 2024, 40( 4): 649- 653. DOI: 10.12449/JCH240401.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (365) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return